Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease

Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in the abundance of Bifidobacterium and Lactobacillus organisms in patients with IBD. The aim of this investigation was to compare the composition...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical microbiology Jg. 52; H. 2; S. 398
Hauptverfasser: Wang, Wei, Chen, Liping, Zhou, Rui, Wang, Xiaobing, Song, Lu, Huang, Sha, Wang, Ge, Xia, Bing
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.02.2014
Schlagworte:
ISSN:1098-660X, 1098-660X
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in the abundance of Bifidobacterium and Lactobacillus organisms in patients with IBD. The aim of this investigation was to compare the compositions of mucosa-associated and fecal bacteria in patients with IBD and in healthy controls (HCs). Fecal and biopsy samples from 21 HCs, 21 and 15 Crohn's disease (CD) patients, and 34 and 29 ulcerative colitis (UC) patients, respectively, were analyzed by quantitative real-time PCR targeting the 16S rRNA gene. The bacterial numbers were transformed into relative percentages for statistical analysis. The proportions of bacteria were uniformly distributed along the colon regardless of the disease state. Bifidobacterium was significantly increased in the biopsy specimens of active UC patients compared to those in the HCs (4.6% versus 2.1%, P = 0.001), and the proportion of Bifidobacterium was significantly higher in the biopsy specimens than in the fecal samples in active CD patients (2.7% versus 2.0%, P = 0.012). The Lactobacillus group was significantly increased in the biopsy specimens of active CD patients compared to those in the HCs (3.4% versus 2.3%, P = 0.036). Compared to the HCs, Faecalibacterium prausnitzii was sharply decreased in both the fecal and biopsy specimens of the active CD patients (0.3% versus 14.0%, P < 0.0001 for fecal samples; 0.8% versus 11.4%, P < 0.0001 for biopsy specimens) and the active UC patients (4.3% versus 14.0%, P = 0.001 for fecal samples; 2.8% versus 11.4%, P < 0.0001 for biopsy specimens). In conclusion, Bifidobacterium and the Lactobacillus group were increased in active IBD patients and should be used more cautiously as probiotics during the active phase of IBD. Butyrate-producing bacteria might be important to gut homeostasis.
AbstractList Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in the abundance of Bifidobacterium and Lactobacillus organisms in patients with IBD. The aim of this investigation was to compare the compositions of mucosa-associated and fecal bacteria in patients with IBD and in healthy controls (HCs). Fecal and biopsy samples from 21 HCs, 21 and 15 Crohn's disease (CD) patients, and 34 and 29 ulcerative colitis (UC) patients, respectively, were analyzed by quantitative real-time PCR targeting the 16S rRNA gene. The bacterial numbers were transformed into relative percentages for statistical analysis. The proportions of bacteria were uniformly distributed along the colon regardless of the disease state. Bifidobacterium was significantly increased in the biopsy specimens of active UC patients compared to those in the HCs (4.6% versus 2.1%, P = 0.001), and the proportion of Bifidobacterium was significantly higher in the biopsy specimens than in the fecal samples in active CD patients (2.7% versus 2.0%, P = 0.012). The Lactobacillus group was significantly increased in the biopsy specimens of active CD patients compared to those in the HCs (3.4% versus 2.3%, P = 0.036). Compared to the HCs, Faecalibacterium prausnitzii was sharply decreased in both the fecal and biopsy specimens of the active CD patients (0.3% versus 14.0%, P < 0.0001 for fecal samples; 0.8% versus 11.4%, P < 0.0001 for biopsy specimens) and the active UC patients (4.3% versus 14.0%, P = 0.001 for fecal samples; 2.8% versus 11.4%, P < 0.0001 for biopsy specimens). In conclusion, Bifidobacterium and the Lactobacillus group were increased in active IBD patients and should be used more cautiously as probiotics during the active phase of IBD. Butyrate-producing bacteria might be important to gut homeostasis.
Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in the abundance of Bifidobacterium and Lactobacillus organisms in patients with IBD. The aim of this investigation was to compare the compositions of mucosa-associated and fecal bacteria in patients with IBD and in healthy controls (HCs). Fecal and biopsy samples from 21 HCs, 21 and 15 Crohn's disease (CD) patients, and 34 and 29 ulcerative colitis (UC) patients, respectively, were analyzed by quantitative real-time PCR targeting the 16S rRNA gene. The bacterial numbers were transformed into relative percentages for statistical analysis. The proportions of bacteria were uniformly distributed along the colon regardless of the disease state. Bifidobacterium was significantly increased in the biopsy specimens of active UC patients compared to those in the HCs (4.6% versus 2.1%, P = 0.001), and the proportion of Bifidobacterium was significantly higher in the biopsy specimens than in the fecal samples in active CD patients (2.7% versus 2.0%, P = 0.012). The Lactobacillus group was significantly increased in the biopsy specimens of active CD patients compared to those in the HCs (3.4% versus 2.3%, P = 0.036). Compared to the HCs, Faecalibacterium prausnitzii was sharply decreased in both the fecal and biopsy specimens of the active CD patients (0.3% versus 14.0%, P < 0.0001 for fecal samples; 0.8% versus 11.4%, P < 0.0001 for biopsy specimens) and the active UC patients (4.3% versus 14.0%, P = 0.001 for fecal samples; 2.8% versus 11.4%, P < 0.0001 for biopsy specimens). In conclusion, Bifidobacterium and the Lactobacillus group were increased in active IBD patients and should be used more cautiously as probiotics during the active phase of IBD. Butyrate-producing bacteria might be important to gut homeostasis.Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in the abundance of Bifidobacterium and Lactobacillus organisms in patients with IBD. The aim of this investigation was to compare the compositions of mucosa-associated and fecal bacteria in patients with IBD and in healthy controls (HCs). Fecal and biopsy samples from 21 HCs, 21 and 15 Crohn's disease (CD) patients, and 34 and 29 ulcerative colitis (UC) patients, respectively, were analyzed by quantitative real-time PCR targeting the 16S rRNA gene. The bacterial numbers were transformed into relative percentages for statistical analysis. The proportions of bacteria were uniformly distributed along the colon regardless of the disease state. Bifidobacterium was significantly increased in the biopsy specimens of active UC patients compared to those in the HCs (4.6% versus 2.1%, P = 0.001), and the proportion of Bifidobacterium was significantly higher in the biopsy specimens than in the fecal samples in active CD patients (2.7% versus 2.0%, P = 0.012). The Lactobacillus group was significantly increased in the biopsy specimens of active CD patients compared to those in the HCs (3.4% versus 2.3%, P = 0.036). Compared to the HCs, Faecalibacterium prausnitzii was sharply decreased in both the fecal and biopsy specimens of the active CD patients (0.3% versus 14.0%, P < 0.0001 for fecal samples; 0.8% versus 11.4%, P < 0.0001 for biopsy specimens) and the active UC patients (4.3% versus 14.0%, P = 0.001 for fecal samples; 2.8% versus 11.4%, P < 0.0001 for biopsy specimens). In conclusion, Bifidobacterium and the Lactobacillus group were increased in active IBD patients and should be used more cautiously as probiotics during the active phase of IBD. Butyrate-producing bacteria might be important to gut homeostasis.
Author Zhou, Rui
Xia, Bing
Wang, Ge
Wang, Wei
Huang, Sha
Wang, Xiaobing
Song, Lu
Chen, Liping
Author_xml – sequence: 1
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
  organization: Department of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China
– sequence: 2
  givenname: Liping
  surname: Chen
  fullname: Chen, Liping
– sequence: 3
  givenname: Rui
  surname: Zhou
  fullname: Zhou, Rui
– sequence: 4
  givenname: Xiaobing
  surname: Wang
  fullname: Wang, Xiaobing
– sequence: 5
  givenname: Lu
  surname: Song
  fullname: Song, Lu
– sequence: 6
  givenname: Sha
  surname: Huang
  fullname: Huang, Sha
– sequence: 7
  givenname: Ge
  surname: Wang
  fullname: Wang, Ge
– sequence: 8
  givenname: Bing
  surname: Xia
  fullname: Xia, Bing
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24478468$$D View this record in MEDLINE/PubMed
BookMark eNpNkE9LAzEQxYNU1Ko3z5Kjl9Ukm6TJUYt_KhUvCt7K7Ga2RnY3NdlF-hX81G5rBWFghjdvfjxmTEZtaJGQM84uORfm6nH6dMm4Yizj-R454syaTGv2Nvo3H5JxSh-McSmVOiCHQsqJkdocke9ZW0aEhI6uYliF2PnQJhoqeuMr70IBZYfR9w2F1tHuHel8UDayr-s-0WUM_Wq7q0Pa3hV9t47QYTbwXF_6dkl3EKC-HaqqoWmgC3FNi_CFNXU-bRKckP0K6oSnu35MXu9uX6YP2fz5fja9nmelYqbLUEmtKqY4AmqFFQhuQVe8EExXEsHmOS-sMJPcMQ5CgFHgnDXOTLTVRS6OycUvdwj42WPqFo1PJdY1tBj6tODS5hMrjbWD9Xxn7YsG3WIVfQNxvfj7n_gBdv12lw
CitedBy_id crossref_primary_10_1007_s00253_018_9465_8
crossref_primary_10_3390_biology12010057
crossref_primary_10_1093_stmcls_sxac014
crossref_primary_10_1136_gutjnl_2018_316250
crossref_primary_10_1016_j_scitotenv_2022_153455
crossref_primary_10_1186_s40168_020_00940_8
crossref_primary_10_3389_fimmu_2023_1185517
crossref_primary_10_1080_19490976_2021_1990827
crossref_primary_10_1093_ibd_izx029
crossref_primary_10_3390_biomedicines13030708
crossref_primary_10_1016_j_bbi_2024_12_027
crossref_primary_10_3390_ani12233435
crossref_primary_10_3389_fcimb_2025_1516010
crossref_primary_10_1016_j_cgh_2020_03_044
crossref_primary_10_1097_QCO_0000000000000300
crossref_primary_10_3390_microorganisms4020020
crossref_primary_10_1016_j_cyto_2014_11_027
crossref_primary_10_1146_annurev_immunol_032414_112151
crossref_primary_10_1002_ame2_12255
crossref_primary_10_3389_fmicb_2017_01703
crossref_primary_10_3390_cells8020193
crossref_primary_10_1016_j_jff_2023_105690
crossref_primary_10_3390_ijms22179170
crossref_primary_10_1038_s41598_017_14889_6
crossref_primary_10_1016_j_copbio_2017_08_004
crossref_primary_10_3390_ijms231911700
crossref_primary_10_1016_j_jaut_2019_01_001
crossref_primary_10_1093_ecco_jcc_jjaa152
crossref_primary_10_1002_cnr2_1863
crossref_primary_10_3390_nu11112605
crossref_primary_10_3390_medicina59091629
crossref_primary_10_1371_journal_pone_0170034
crossref_primary_10_3389_fcell_2025_1514636
crossref_primary_10_1016_j_bbrc_2018_01_116
crossref_primary_10_1016_j_dld_2018_11_021
crossref_primary_10_1007_s11894_015_0439_z
crossref_primary_10_1128_spectrum_00616_22
crossref_primary_10_1097_MIB_0000000000000215
crossref_primary_10_1093_ismejo_wrae226
crossref_primary_10_3390_microorganisms12091864
crossref_primary_10_3390_microorganisms7100440
crossref_primary_10_1016_j_ecoenv_2025_118910
crossref_primary_10_1111_jpn_13703
crossref_primary_10_3389_fcimb_2021_739707
crossref_primary_10_1186_s13099_024_00654_4
crossref_primary_10_3390_ijms252010879
crossref_primary_10_1186_s12917_022_03510_2
crossref_primary_10_3389_fcimb_2019_00112
crossref_primary_10_3389_fphar_2022_972351
crossref_primary_10_1186_s13075_014_0486_0
crossref_primary_10_1159_000495115
crossref_primary_10_1016_j_celrep_2025_115553
crossref_primary_10_3748_wjg_v23_i25_4624
crossref_primary_10_1111_ene_15607
crossref_primary_10_1016_j_carbpol_2019_115460
crossref_primary_10_1097_MCG_0000000000001170
crossref_primary_10_3389_fmicb_2022_856165
crossref_primary_10_1016_j_rmed_2025_108077
crossref_primary_10_1111_adb_12869
crossref_primary_10_1155_2014_872725
crossref_primary_10_1128_msystems_00602_24
crossref_primary_10_3389_fphys_2021_662739
crossref_primary_10_1096_fj_202100920RR
crossref_primary_10_1016_j_biopha_2025_118513
crossref_primary_10_1016_j_dld_2015_09_005
crossref_primary_10_1177_2050640619876787
crossref_primary_10_3389_fnut_2021_818902
crossref_primary_10_1186_s12876_020_01444_3
crossref_primary_10_1093_gastro_goae074
crossref_primary_10_1186_s12906_021_03337_8
crossref_primary_10_3390_nu15061338
crossref_primary_10_1126_sciimmunol_adm6843
crossref_primary_10_1016_j_transproceed_2015_12_040
crossref_primary_10_1155_2023_7333511
crossref_primary_10_3390_gastroent12020018
crossref_primary_10_1016_j_chom_2024_08_010
crossref_primary_10_4049_jimmunol_1601621
crossref_primary_10_1038_ncomms12015
crossref_primary_10_1002_eji_202249866
crossref_primary_10_3748_wjg_v25_i36_5543
crossref_primary_10_1002_cpt_2952
crossref_primary_10_1053_j_gastro_2020_11_050
crossref_primary_10_1111_jgh_16043
crossref_primary_10_3390_biomedicines11102658
crossref_primary_10_1186_s12876_019_0930_3
crossref_primary_10_3390_nu13082661
crossref_primary_10_1186_s13073_017_0428_y
crossref_primary_10_3389_fimmu_2019_00277
crossref_primary_10_1177_17562848241258360
crossref_primary_10_1177_1352458516682105
crossref_primary_10_2147_JIR_S449335
crossref_primary_10_3390_molecules29020379
crossref_primary_10_1097_MIB_0000000000000307
crossref_primary_10_1038_s41598_018_37143_z
crossref_primary_10_1080_19490976_2024_2341457
crossref_primary_10_1016_j_tifs_2022_09_012
crossref_primary_10_3390_immuno2040042
crossref_primary_10_1093_ecco_jcc_jjaa227
crossref_primary_10_1128_AEM_02766_16
crossref_primary_10_1186_s40168_018_0520_6
crossref_primary_10_3390_jcm8091291
crossref_primary_10_1093_ibd_izaa188
crossref_primary_10_3390_nu12051284
crossref_primary_10_1016_j_jep_2022_115145
crossref_primary_10_4103_sjg_sjg_368_22
crossref_primary_10_1016_S1875_5364_24_60600_X
crossref_primary_10_3390_pathogens10020152
crossref_primary_10_1017_S0954422415000037
crossref_primary_10_1038_srep35216
crossref_primary_10_3389_fimmu_2020_603594
crossref_primary_10_1089_jmf_2017_0138
crossref_primary_10_1186_s13020_022_00633_4
crossref_primary_10_1186_s12864_018_5306_5
crossref_primary_10_1080_1744666X_2021_1850269
crossref_primary_10_1016_j_jff_2023_105411
crossref_primary_10_1371_journal_pone_0184394
crossref_primary_10_1016_j_jare_2025_05_015
crossref_primary_10_1093_ibd_izac156
crossref_primary_10_3390_jcm9061748
crossref_primary_10_3389_fendo_2023_1220044
crossref_primary_10_1111_exd_14420
crossref_primary_10_3389_fcimb_2022_837019
crossref_primary_10_1038_srep39399
crossref_primary_10_3389_fimmu_2021_658354
crossref_primary_10_1186_s12918_018_0667_6
crossref_primary_10_20935_AcadMolBioGen7642
crossref_primary_10_1093_jn_nxab250
crossref_primary_10_1016_j_micres_2022_127019
crossref_primary_10_1016_j_micpath_2025_108059
crossref_primary_10_1109_TCBB_2018_2831212
crossref_primary_10_3390_ijms24097998
crossref_primary_10_1016_j_suronc_2019_11_005
crossref_primary_10_1111_apt_16096
crossref_primary_10_1038_srep26087
crossref_primary_10_1038_s41420_023_01666_w
crossref_primary_10_1128_mSystems_00507_21
crossref_primary_10_1016_j_anaerobe_2022_102652
crossref_primary_10_3390_biom10050766
crossref_primary_10_3390_nu16070989
crossref_primary_10_1007_s13668_023_00475_y
crossref_primary_10_1097_JCMA_0000000000000532
crossref_primary_10_1186_s40168_023_01483_4
crossref_primary_10_31146_1682_8658_ecg_220_12_164_182
crossref_primary_10_1038_mi_2014_122
crossref_primary_10_3390_ijms25052753
crossref_primary_10_1093_ibd_izz011
crossref_primary_10_1093_ecco_jcc_jjz077
crossref_primary_10_3389_fmicb_2022_1081591
crossref_primary_10_1186_s12866_024_03368_4
crossref_primary_10_1016_j_foodres_2022_111390
crossref_primary_10_1080_00365521_2016_1216587
crossref_primary_10_3389_fmicb_2019_02101
crossref_primary_10_1038_s41598_022_17296_8
crossref_primary_10_3390_metabo13070873
crossref_primary_10_3390_cells11060944
crossref_primary_10_1111_jch_14598
crossref_primary_10_1016_j_cpr_2020_101943
crossref_primary_10_1017_S0033291722000897
crossref_primary_10_3389_fcimb_2023_1127041
crossref_primary_10_1111_odi_12676
crossref_primary_10_1016_j_micres_2023_127470
crossref_primary_10_1093_ecco_jcc_jjz049
crossref_primary_10_1097_MOG_0000000000000285
crossref_primary_10_3390_ijerph17197081
crossref_primary_10_1038_s41419_021_03395_3
crossref_primary_10_3390_cancers14184403
crossref_primary_10_1186_s12866_023_02999_3
crossref_primary_10_1016_j_micpath_2020_104707
crossref_primary_10_3390_nu14245270
crossref_primary_10_1097_MPG_0000000000000950
crossref_primary_10_1080_13543784_2018_1483333
crossref_primary_10_1016_j_jaut_2023_103062
crossref_primary_10_3390_pathogens8030126
crossref_primary_10_1016_j_ijpharm_2018_01_010
crossref_primary_10_1007_s00253_021_11646_8
crossref_primary_10_1016_j_jff_2024_106414
crossref_primary_10_1016_j_foodres_2022_112010
crossref_primary_10_1038_s41522_020_0119_0
crossref_primary_10_1038_s41551_022_00972_5
crossref_primary_10_1016_j_biopha_2020_109914
crossref_primary_10_7717_peerj_13205
crossref_primary_10_1128_cmr_00210_24
crossref_primary_10_14309_ajg_0000000000000305
crossref_primary_10_1016_j_advms_2020_06_003
crossref_primary_10_1007_s00248_018_1176_2
crossref_primary_10_1038_s41598_020_62811_4
crossref_primary_10_1016_j_biopha_2024_117302
crossref_primary_10_1097_MD_0000000000041262
crossref_primary_10_1097_MIB_0000000000000970
crossref_primary_10_3389_fmed_2022_1000563
crossref_primary_10_5487_TR_2014_30_1_027
crossref_primary_10_3389_fimmu_2024_1399842
crossref_primary_10_3389_fmicb_2022_999001
crossref_primary_10_1007_s10620_020_06133_5
crossref_primary_10_1080_00365521_2023_2223708
crossref_primary_10_1073_pnas_2218739120
crossref_primary_10_3390_microorganisms10112190
crossref_primary_10_3390_ijms26178196
crossref_primary_10_1053_j_gastro_2014_03_001
crossref_primary_10_3389_fmicb_2024_1492783
crossref_primary_10_1007_s13311_017_0574_3
crossref_primary_10_1007_s10096_017_2955_2
crossref_primary_10_1093_femsle_fnab149
crossref_primary_10_1007_s11481_021_10022_7
crossref_primary_10_3389_fmicb_2017_01896
crossref_primary_10_1186_s12906_019_2750_y
crossref_primary_10_1007_s12026_025_09655_0
crossref_primary_10_1016_j_bbrc_2025_151584
crossref_primary_10_1038_s41522_025_00714_w
crossref_primary_10_1016_j_biopha_2023_114763
crossref_primary_10_3389_fphar_2024_1428242
crossref_primary_10_3390_nu14010004
crossref_primary_10_1111_1758_2229_12411
crossref_primary_10_3389_fmed_2021_716816
crossref_primary_10_3389_fimmu_2016_00290
crossref_primary_10_3390_microorganisms10051044
crossref_primary_10_1053_j_gastro_2019_11_294
crossref_primary_10_1097_MIB_0000000000000641
crossref_primary_10_1016_j_jaci_2018_06_024
crossref_primary_10_3390_ijms25084258
crossref_primary_10_1016_j_molimm_2020_03_008
crossref_primary_10_1177_0963689719873890
crossref_primary_10_1016_j_mam_2025_101349
crossref_primary_10_1177_0023677218818605
crossref_primary_10_1177_2050640619867555
crossref_primary_10_1080_08923973_2018_1469144
crossref_primary_10_1111_asj_13584
crossref_primary_10_1016_j_jiac_2015_07_010
crossref_primary_10_3390_vaccines9060584
crossref_primary_10_1097_MD_0000000000000051
crossref_primary_10_1017_gmb_2022_3
crossref_primary_10_1159_000505036
crossref_primary_10_3389_fmicb_2023_1273269
crossref_primary_10_3390_ijms241713338
crossref_primary_10_1136_egastro_2023_100055
crossref_primary_10_1016_j_carbpol_2025_124097
crossref_primary_10_1017_gmb_2022_5
crossref_primary_10_3390_cells9102283
crossref_primary_10_1093_ibd_izy085
crossref_primary_10_1016_j_anifeedsci_2022_115372
crossref_primary_10_1016_j_sjbs_2018_11_008
crossref_primary_10_1111_ene_13026
crossref_primary_10_1186_s13063_020_04523_8
crossref_primary_10_3390_microorganisms11112750
crossref_primary_10_3390_nu16020247
crossref_primary_10_1007_s00248_019_01462_z
crossref_primary_10_1186_s40104_024_00995_9
crossref_primary_10_1038_s41598_024_54257_9
crossref_primary_10_3389_fnut_2023_1130841
crossref_primary_10_3390_ijms26062503
crossref_primary_10_1134_S1990750816020037
crossref_primary_10_1039_D2FO01165D
crossref_primary_10_32604_biocell_2023_025311
crossref_primary_10_1007_s42485_021_00062_1
crossref_primary_10_3389_fimmu_2023_1004756
crossref_primary_10_3390_ijms26072939
crossref_primary_10_1111_1469_0691_12799
crossref_primary_10_1038_s41467_025_56829_3
crossref_primary_10_1016_j_biopha_2025_118268
crossref_primary_10_3390_microorganisms4030034
crossref_primary_10_1016_j_isci_2024_110853
crossref_primary_10_3390_ijms23158494
crossref_primary_10_1371_journal_pone_0300678
crossref_primary_10_1016_j_anaerobe_2017_02_010
crossref_primary_10_1097_MCG_0000000000000772
crossref_primary_10_1371_journal_pone_0276910
crossref_primary_10_3390_fermentation9090827
crossref_primary_10_1093_ecco_jcc_jjac001
crossref_primary_10_3389_fvets_2024_1456181
crossref_primary_10_1038_pr_2015_115
crossref_primary_10_1371_journal_pone_0277576
crossref_primary_10_3390_ijms20020283
crossref_primary_10_1002_mnfr_201800160
crossref_primary_10_3389_fmed_2022_1023896
crossref_primary_10_3390_microorganisms12112333
crossref_primary_10_1128_CMR_00060_18
crossref_primary_10_3390_nu13093157
crossref_primary_10_1038_s41467_022_34667_x
crossref_primary_10_1186_s13293_024_00590_7
crossref_primary_10_3390_nu12051423
crossref_primary_10_3748_wjg_v27_i23_3317
crossref_primary_10_3390_ijms22063076
crossref_primary_10_1097_MIB_0000000000000029
crossref_primary_10_1002_jsfa_12254
crossref_primary_10_1016_j_bcp_2018_07_044
crossref_primary_10_1007_s10620_016_4229_8
crossref_primary_10_3389_fimmu_2021_674313
crossref_primary_10_3390_cancers15061913
crossref_primary_10_1038_s41531_025_00894_4
crossref_primary_10_1186_s40168_016_0176_z
crossref_primary_10_3390_nu14020260
crossref_primary_10_1039_D3FO05337G
crossref_primary_10_3390_nu10081055
crossref_primary_10_1080_19490976_2021_1907270
crossref_primary_10_3748_wjg_v20_i40_14805
crossref_primary_10_1016_j_heliyon_2021_e06432
crossref_primary_10_1038_s41591_018_0308_z
crossref_primary_10_3390_microorganisms10010073
crossref_primary_10_3390_ijms22063061
crossref_primary_10_13105_wjma_v8_i2_54
crossref_primary_10_1136_bmjopen_2018_021987
crossref_primary_10_1002_jsfa_12382
crossref_primary_10_1111_jgh_15222
crossref_primary_10_3390_microorganisms9050977
crossref_primary_10_1186_s12915_023_01748_2
crossref_primary_10_3390_nu12123749
crossref_primary_10_3390_nu16060773
crossref_primary_10_1371_journal_pone_0116465
crossref_primary_10_3390_ijms241914925
crossref_primary_10_3390_ph17040490
crossref_primary_10_1038_s41598_019_49829_z
crossref_primary_10_1128_spectrum_00823_24
crossref_primary_10_3389_fonc_2022_813745
crossref_primary_10_3389_fimmu_2018_03183
crossref_primary_10_1002_mdc3_12840
crossref_primary_10_3389_fcimb_2017_00051
crossref_primary_10_2147_DMSO_S291822
crossref_primary_10_1016_j_prmcm_2025_100655
crossref_primary_10_3390_ijms26073148
crossref_primary_10_1007_s10753_023_01870_x
crossref_primary_10_1093_femsre_fuaa015
crossref_primary_10_3389_fmicb_2023_1202768
crossref_primary_10_3389_fnut_2021_778542
crossref_primary_10_3390_ani12010123
crossref_primary_10_3390_nu11112629
crossref_primary_10_1007_s00108_013_3443_0
crossref_primary_10_3389_fmicb_2019_00322
crossref_primary_10_1007_s00281_014_0454_4
crossref_primary_10_3748_wjg_v20_i28_9468
crossref_primary_10_1212_NXI_0000000000000907
crossref_primary_10_1093_ecco_jcc_jjad204
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1128/JCM.01500-13
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1098-660X
ExternalDocumentID 24478468
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
.55
.GJ
0R~
18M
29K
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
AAGFI
ABOCM
ABPPZ
ACGFO
ADBBV
AENEX
AGCDD
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
D-I
DIK
DU5
E3Z
EBS
ECM
EIF
EJD
F5P
FRP
GX1
H13
HF~
HYE
HZ~
H~9
KQ8
L7B
NPM
O9-
OHT
OK1
P2P
P6G
RHI
RNS
RPM
RSF
TR2
VH1
W8F
WHG
WOQ
X7M
ZCA
ZGI
ZXP
~KM
7X8
ID FETCH-LOGICAL-c508t-e5465f051eae65efa219a6f1b206f4ea9331b92873d01a22a85add98d87696b32
IEDL.DBID 7X8
ISICitedReferencesCount 392
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000330444200005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1098-660X
IngestDate Thu Sep 04 17:36:23 EDT 2025
Mon Jul 21 06:05:33 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-e5465f051eae65efa219a6f1b206f4ea9331b92873d01a22a85add98d87696b32
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://jcm.asm.org/content/jcm/52/2/398.full.pdf
PMID 24478468
PQID 1493794899
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1493794899
pubmed_primary_24478468
PublicationCentury 2000
PublicationDate 2014-Feb
20140201
PublicationDateYYYYMMDD 2014-02-01
PublicationDate_xml – month: 02
  year: 2014
  text: 2014-Feb
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical microbiology
PublicationTitleAlternate J Clin Microbiol
PublicationYear 2014
References 22520466 - Cell Host Microbe. 2012 Apr 19;11(4):387-96
14517348 - Mol Cancer Res. 2003 Sep;1(11):855-62
19756155 - PLoS One. 2009;4(9):e7056
21530738 - Gastroenterology. 2011 May;140(6):1720-28
12089021 - Appl Environ Microbiol. 2002 Jul;68(7):3401-7
17119388 - Inflamm Bowel Dis. 2006 Dec;12(12):1136-45
19197385 - PLoS One. 2009;4(2):e4365
17890331 - Appl Environ Microbiol. 2007 Nov;73(22):7435-42
17699621 - Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13780-5
18242222 - Gastroenterology. 2008 Feb;134(2):577-94
11375166 - Appl Environ Microbiol. 2001 Jun;67(6):2578-85
18936492 - Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
3569765 - Gastroenterology. 1987 Jun;92(6):1894-8
15867587 - Inflamm Bowel Dis. 2005 May;11(5):473-80
19343057 - Nat Rev Immunol. 2009 May;9(5):313-23
15479682 - Gut. 2004 Nov;53(11):1617-23
21219646 - BMC Microbiol. 2011;11:7
18590586 - Br J Nutr. 2009 Feb;101(4):541-50
21282652 - Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4623-30
16000463 - J Clin Microbiol. 2005 Jul;43(7):3380-9
19174792 - Am J Gastroenterol. 2009 Feb;104(2):437-43
22693446 - PLoS Pathog. 2012;8(5):e1002714
15867588 - Inflamm Bowel Dis. 2005 May;11(5):481-7
19026645 - Gastroenterology. 2009 Jan;136(1):65-80
20816835 - Gastroenterology. 2010 Dec;139(6):1844-1854.e1
19714743 - Inflamm Bowel Dis. 2010 Mar;16(3):390-400
12374228 - Scand J Gastroenterol. 2002 Sep;37(9):1034-41
22132181 - PLoS One. 2011;6(11):e27961
1248701 - Gastroenterology. 1976 Mar;70(3):439-44
12524406 - Gut. 2003 Feb;52(2):237-42
22301383 - Gut. 2012 Jul;61(7):1007-15
19273135 - Front Biosci (Landmark Ed). 2009;14:1362-86
16696804 - Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74
16819502 - Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407
20517305 - Am J Gastroenterol. 2010 Oct;105(10):2218-27
15569116 - Aliment Pharmacol Ther. 2004 Nov 15;20(10):1133-41
19023901 - Inflamm Bowel Dis. 2009 May;15(5):653-60
11781279 - Gastroenterology. 2002 Jan;122(1):44-54
16988018 - J Clin Microbiol. 2006 Nov;44(11):3980-8
16648155 - Gut. 2006 Dec;55(12):1760-7
15574920 - Appl Environ Microbiol. 2004 Dec;70(12):7220-8
19235917 - Inflamm Bowel Dis. 2009 Jul;15(7):1022-31
17956582 - Clin Exp Immunol. 2007 Dec;150(3):531-8
19390523 - Obesity (Silver Spring). 2009 Oct;17(10):1906-15
22155109 - Am J Pathol. 2012 Feb;180(2):626-35
23044767 - Am J Gastroenterol. 2012 Dec;107(12):1913-22
12406736 - Appl Environ Microbiol. 2002 Nov;68(11):5445-51
References_xml – reference: 15867587 - Inflamm Bowel Dis. 2005 May;11(5):473-80
– reference: 22155109 - Am J Pathol. 2012 Feb;180(2):626-35
– reference: 22520466 - Cell Host Microbe. 2012 Apr 19;11(4):387-96
– reference: 18590586 - Br J Nutr. 2009 Feb;101(4):541-50
– reference: 17699621 - Proc Natl Acad Sci U S A. 2007 Aug 21;104(34):13780-5
– reference: 19714743 - Inflamm Bowel Dis. 2010 Mar;16(3):390-400
– reference: 12089021 - Appl Environ Microbiol. 2002 Jul;68(7):3401-7
– reference: 19273135 - Front Biosci (Landmark Ed). 2009;14:1362-86
– reference: 12406736 - Appl Environ Microbiol. 2002 Nov;68(11):5445-51
– reference: 17890331 - Appl Environ Microbiol. 2007 Nov;73(22):7435-42
– reference: 19390523 - Obesity (Silver Spring). 2009 Oct;17(10):1906-15
– reference: 17119388 - Inflamm Bowel Dis. 2006 Dec;12(12):1136-45
– reference: 15479682 - Gut. 2004 Nov;53(11):1617-23
– reference: 22301383 - Gut. 2012 Jul;61(7):1007-15
– reference: 16648155 - Gut. 2006 Dec;55(12):1760-7
– reference: 20816835 - Gastroenterology. 2010 Dec;139(6):1844-1854.e1
– reference: 15574920 - Appl Environ Microbiol. 2004 Dec;70(12):7220-8
– reference: 19174792 - Am J Gastroenterol. 2009 Feb;104(2):437-43
– reference: 19197385 - PLoS One. 2009;4(2):e4365
– reference: 14517348 - Mol Cancer Res. 2003 Sep;1(11):855-62
– reference: 17956582 - Clin Exp Immunol. 2007 Dec;150(3):531-8
– reference: 16696804 - Aliment Pharmacol Ther. 2006 Jun 1;23(11):1567-74
– reference: 11375166 - Appl Environ Microbiol. 2001 Jun;67(6):2578-85
– reference: 22132181 - PLoS One. 2011;6(11):e27961
– reference: 18936492 - Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
– reference: 16988018 - J Clin Microbiol. 2006 Nov;44(11):3980-8
– reference: 19023901 - Inflamm Bowel Dis. 2009 May;15(5):653-60
– reference: 3569765 - Gastroenterology. 1987 Jun;92(6):1894-8
– reference: 18242222 - Gastroenterology. 2008 Feb;134(2):577-94
– reference: 21219646 - BMC Microbiol. 2011;11:7
– reference: 15867588 - Inflamm Bowel Dis. 2005 May;11(5):481-7
– reference: 12374228 - Scand J Gastroenterol. 2002 Sep;37(9):1034-41
– reference: 23044767 - Am J Gastroenterol. 2012 Dec;107(12):1913-22
– reference: 21282652 - Proc Natl Acad Sci U S A. 2011 Mar 15;108 Suppl 1:4623-30
– reference: 16819502 - Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):390-407
– reference: 11781279 - Gastroenterology. 2002 Jan;122(1):44-54
– reference: 16000463 - J Clin Microbiol. 2005 Jul;43(7):3380-9
– reference: 19235917 - Inflamm Bowel Dis. 2009 Jul;15(7):1022-31
– reference: 15569116 - Aliment Pharmacol Ther. 2004 Nov 15;20(10):1133-41
– reference: 21530738 - Gastroenterology. 2011 May;140(6):1720-28
– reference: 20517305 - Am J Gastroenterol. 2010 Oct;105(10):2218-27
– reference: 22693446 - PLoS Pathog. 2012;8(5):e1002714
– reference: 19756155 - PLoS One. 2009;4(9):e7056
– reference: 19343057 - Nat Rev Immunol. 2009 May;9(5):313-23
– reference: 19026645 - Gastroenterology. 2009 Jan;136(1):65-80
– reference: 12524406 - Gut. 2003 Feb;52(2):237-42
– reference: 1248701 - Gastroenterology. 1976 Mar;70(3):439-44
SSID ssj0014455
Score 2.59633
Snippet Dysbiosis in the intestinal microbiota of persons with inflammatory bowel disease (IBD) has been described, but there are still varied reports on changes in...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 398
SubjectTerms Adolescent
Adult
Bacterial Load
Bifidobacterium - isolation & purification
Biopsy
Biota
Butyrates - metabolism
Dysbiosis - microbiology
Feces - microbiology
Female
Gastrointestinal Tract - microbiology
Humans
Inflammatory Bowel Diseases - microbiology
Intestinal Mucosa - microbiology
Lactobacillus - isolation & purification
Male
Middle Aged
Real-Time Polymerase Chain Reaction
RNA, Bacterial - genetics
RNA, Ribosomal, 16S - genetics
Young Adult
Title Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease
URI https://www.ncbi.nlm.nih.gov/pubmed/24478468
https://www.proquest.com/docview/1493794899
Volume 52
WOSCitedRecordID wos000330444200005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFA7qVHzxMm_zRgRf49omzdonUXGIbGMPKnsbSZtAoWvnLsr-gr_akzRjT4IglD60pJT0O-d8yTk9H0I3XIbC1xElCYQPwgDCJJZaEB4yRUMI-cLKt713Wr1eNBjEfbfhNnVllUufaB11WiZmj7wJTJ4CdmB5cDf-IEY1ymRXnYTGOqpRoDKmpKs1WGURGLOqp77pmcm5N1gWvgdR8-Wxe2sW-x4xwga_kUsbZNp7_329fbTr6CW-r_BwgNZUUUdbleDkoo62uy6Vfoi-wTOYgnSV4rFRSphYAOJS44dMZymYuW3jPB9hUaQYaCLuGGkeuJzl-XyK7e8g9l4OcdaMk_PZwjSeIGPbRRZiInYPETgr4NCAvpHN6mNZfqkcu-zQEXprP70-PhMnzEAS4HMzooyCugZzVkLxUGkBbk9w7cvA45opEVPqyxjWYjT1fBEEIgrBjcZRCq435pIGx2ijKAt1inAkhRTAkRijCUsEl0GiDctMFOVUsLiBrpfzPQTgm2yGKFQ5nw5XM95AJ9VHG46rDh1D4CwtIFbR2R9Gn6MdIEGsqsS-QDUNZq8u0WbyOcumkyuLKDj3-t0fcqzYUQ
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+proportions+of+Bifidobacterium+and+the+Lactobacillus+group+and+loss+of+butyrate-producing+bacteria+in+inflammatory+bowel+disease&rft.jtitle=Journal+of+clinical+microbiology&rft.au=Wang%2C+Wei&rft.au=Chen%2C+Liping&rft.au=Zhou%2C+Rui&rft.au=Wang%2C+Xiaobing&rft.date=2014-02-01&rft.issn=1098-660X&rft.eissn=1098-660X&rft.volume=52&rft.issue=2&rft.spage=398&rft_id=info:doi/10.1128%2FJCM.01500-13&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-660X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-660X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-660X&client=summon